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aspiration: A safe bridge to accurate diagnosisEndoscopic ultrasound (EUS) is a good adjunctive tool for
evaluating lesions of the gastrointestinal (GI) tract and
surrounding organs. Besides imaging assessment, EUS has
become a popular method for procuring diagnostic tissue by
fine-needle aspiration (FNA). EUSeFNA involves passing a
19- to 25-gauge (most commonly a 22-gauge) aspiration
needle through the working channel of a curvilinear
echoendoscope under real-time guidance into an EUS-
visualized lesion. Although EUSeFNA plays only a limited
role in submucosal tumor tissue acquisition with a modest
diagnostic yield of 70e84% [1], it can offer a highly sensi-
tive and specific cytological diagnosis at rates of 85% and
98% in pancreatic cancer patients, respectively, with esti-
mates suggesting corresponding rates of 90% and 100% in
most other patients [2,3]. At present, EUSeFNA is
frequently incorporated into the algorithms for assessment
and management of patients with mediastinal and
abdominal tumors [4]. In National Comprehensive Cancer
Network clinical practice guidelines, EUSeFNA is the
preferred tissue sampling method in pancreatic cancer
patients for both borderline resectable pancreatic tumors
before planned neoadjuvant therapy and locally advanced
unresectable pancreatic tumors before treatment, and an
important diagnostic tool in patients with non-small cell
lung cancer for pathologic mediastinal lymph node
evaluation [5,6]. In addition to alteration of patient man-
agement after a definite cytopathologic diagnosis or tumor
staging, EUSeFNA also has an impact on facilitating medical
decision making of both patients and physicians [4]. The
role of EUSeFNA is getting increasingly important in our
daily clinical practice.
On performing EUSeFNA, a minimally invasive proce-
dure, there are still some inherent adverse events. The
most common complications after EUSeFNA are hemor-
rhage, pancreatitis, and infection at rates of 1e4%, 1e2%,
and 0.4e1%, respectively. Most patients with complications
can recover with conservative therapy [7]. In comparison
with percutaneous approach guided by computerized to-
mography, EUSeFNA has several advantages on safety is-
sues, including adopting real-time ultrasound forhttp://dx.doi.org/10.1016/j.aidm.2015.03.001
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avoid mispuncture-related complications, utilizing Doppler
ultrasound to reduce the possibility of developing trau-
matic vascular puncture, and providing a shorter punc-
turing route with a potentially lower risk of needle-tract
seeding [8].
In this issue, Yang and colleagues [11] present a single-
center experience on EUSeFNA for solid tumors during a
study period of 8 years. They have performed EUSeFNA for
patients with submucosal, mediastinal, pancreatic, and
other abdominal tumors, and focal transmural thickening of
the GI tract. Excluding submucosal tumors, they report that
the overall diagnostic accuracy for malignancy to be 82.9%.
Similar to previous studies, a lower diagnostic yield of 61%
was reported for the submucosal tumors. Three cases
(1.3%, 3/233) with complications occurred and recovered
uneventfully in this study. They concluded that EUSeFNA
was a safe and effective method for diagnosis of medias-
tinal and abdominal solid tumors.
For further improving EUSeFNA diagnostic accuracy,
adequate mentored training and accumulated experience
are necessary for this highly operator-dependent procedure
[9]. Operator factor plays a pivotal role in accurate diag-
nosis of EUSeFNA despite current advances in instruments
and refinements in techniques. Besides, an experienced
cytopathologist is also an important element in the suc-
cessful diagnostic teamwork. Rapid on-site cytopathology
evaluation, which was not available in Yang et al’s study,
may improve diagnostic yield and lower rates of insufficient
aspirates and repeat procedures [10].
In summary, EUSeFNA can offer a safe bridge to make an
accurate cytopathologic diagnosis of both subepithelial and
extraluminal lesions along the GI tract. EUSeFNA is a good
tool helpful for decision making and future management
planning after a definite diagnosis.
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